MTOR and neoplasm: Rapalogs (temsirolimus, everolimus), ATP-competitive mTOR inhibitors (MLN0128, PP242, AZD2014, AZD8055) and dual PI3K/mTOR inhibitors (NVP- BEZ235, LY3023414, etc.)have been applied to treat a variety of cancers, and the mTORC1/2 inhibitor onatasertib (ATG-008) demonstrates synergistic anti-tumor activity in combination with PD-1 antibody [180, 181].